Period:
Draw Mode:
| Volume | 1,109,447 |
|
|||||
| News | (1) | ||||||
| Day High | 273.61 | Low High |
|||||
| Day Low | 267.41 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | AMGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -1.58 | -0.59% | 267.46 | 13:22:19 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 271.73 | 267.41 | 273.61 | 269.04 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 27,628 | 1,109,447 | $ 270.34 | $ 299,928,545 | - | 211.73 - 296.67 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:22:25 | 26 | $ 267.3866 | USD |
Amgen (AMGN) Options Flow Summary
Amgen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 143.06B | 534.90M | - | 26.32B | 6.55B | 12.25 | 21.89 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Amgen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AMGN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 265.00 | 273.61 | 263.97 | 269.32 | 2,395,211 | 2.46 | 0.93% |
| 1 Month | 260.00 | 273.61 | 248.38 | 261.63 | 2,311,284 | 7.46 | 2.87% |
| 3 Months | 224.66 | 273.61 | 218.45 | 248.84 | 2,504,064 | 42.80 | 19.05% |
| 6 Months | 239.61 | 273.61 | 211.73 | 239.42 | 2,431,619 | 27.85 | 11.62% |
| 1 Year | 227.11 | 296.67 | 211.73 | 249.25 | 2,551,347 | 40.35 | 17.77% |
| 3 Years | 247.67 | 296.67 | 198.64 | 238.75 | 2,702,212 | 19.79 | 7.99% |
| 5 Years | 207.41 | 296.67 | 165.06 | 226.03 | 2,721,418 | 60.05 | 28.95% |
Amgen Description
| Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira). |